Zinc Oxide Nanoparticles for their Anti-Convulsant Property: A Comprehensive Review

Zinc Oxide Nanoparticles (ZnO NPs) have garnered interest for their potential anti-convulsant properties, offering a promising approach to epilepsy treatment. Their unique physicochemical traits, such as a large surface area and inherent antioxidant capacities, make ZnO NPs potent inhibitors of oxidative stress, a key factor in epileptogenesis. Experimental models have shown that ZnO NPs can reduce Reactive Oxygen Species (ROS) levels and protect against brain injury. By influencing neurotransmitter release, including glutamate and GABA, ZnO NPs help maintain the excitatory-inhibitory balance in the brain, potentially reducing seizure likelihood. Their nanoscale size facilitates effective blood-brain barrier crossing, enhancing the bioavailability of traditional anti-convulsant medications and boosting their therapeutic effects. ZnO NPs offer neuroprotection by regulating calcium influx and preserving neuronal membranes, defending neurons against excitotoxicity, common in seizures. Additionally, they enhance drug delivery by acting as carriers, increasing the bioavailability of standard anti-epileptic drugs and potentially improving treatment outcomes while minimizing side effects. In conclusion, ZnO NPs antioxidant properties, neurotransmission modulation, and drug delivery capabilities position them as a promising adjunct therapy for epilepsy. Further research is essential to maximize their therapeutic potential and ensure safety.